Search results
Pfizer's DMD gene therapy falls short in phase 3 trial
Becker’s Hospital Review· 5 days agoPfizer's gene therapy candidate for Duchenne muscular dystrophy failed to meet its primary endpoint in a phase 3 trial, the company said ...
Cranbury Pharmaceuticals Receives FDA Approval for First Generic Version of Emflaza Oral Suspension
New Jersey Business Magazine· 5 days agoCranbury Pharmaceuticals, a wholly-owned subsidiary of Tris Pharma, today announced the U.S. Food...
Pfizer's Duchenne gene therapy fails in late-stage study
AOL· 6 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the study such the time it takes for patients to rise from the floor or improve speed in a 10 ...
Health Care Roundup: Market Talk
The Wall Street Journal· 5 days agoPublished exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0748 ET – The failure of Pfizer’s proposed gene therapy for Duchenne ...
Sarepta Jumps After Rival Gene Therapy From Pfizer Flops
Investor's Business Daily· 5 days agoThe news gives Sarepta Therapeutics (SRPT) an edge heading to June 21, when the Food and Drug Administration will decide whether to fully approve Elevidys for patients with the muscle-wasting ...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails -...
Benzinga· 4 days agoPfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
MarionMade!: Running to help others who may not be able to walk
The Marion Star via Yahoo News· 2 days agoThe family then started My DMD hero in 2019 to help other families. “The goal is to meet Duchenne...
Biophytis Announces the Successful Industrial Transfer of BIO101
Digital Journal· 6 days agoThis batch is now available for use in Biophytis' clinical development programme to treat respiratory deterioration in patients with Duchenne Muscular & ...
WATCH: Organization modifies Valley family's home for free to help kids in wheelchairs
ABC 15 Phoenix· 4 days agoA Valley family is navigating day-to-day life a little easier thanks to a local organization’s...
Analysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $164.00
ETF DAILY NEWS· 16 hours agoShares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) have received a consensus rating of “Moderate Buy” from the fifteen analysts that are presently covering the stock, Marketbeat.com ...
